The role of cytokines in breast cancer development and progression

Journal of Interferon and Cytokine Research

Volumn 35, Issue 1, 2015, Pages 1-16

  Esquivel Velázquez, Marcela ^a   Ostoa Saloma, Pedro ^a   Palacios Arreola, Margarita Isabel ^a   Nava Castro, Karen E ^b   Castro, Julieta Ivonne ^b   Morales Montor, Jorge ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b HOSPITAL GENERAL DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; COLONY STIMULATING FACTOR; CYTOKINE; INTERFERON; INTERLEUKIN 17; INTERLEUKIN 19; INTERLEUKIN 20; INTERLEUKIN 23; INTERLEUKIN 6; SECRETORY PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CELL COMMUNICATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE EVASION; IMMUNE SYSTEM; INFLAMMATION; METASTASIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; BREAST TUMOR; CELL TRANSFORMATION; DISEASE COURSE; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS; TUMOR ESCAPE;

ADIPOKINES; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; QUALITY OF LIFE; TUMOR ESCAPE;

EID: 84921030659     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0026     Document Type: Review

References (221)

1. Aharinejad S, Abraham D, Paulus P, Abri H, Hofmann M, Grossschmidt K, Hofbauer R. 2002. Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice. Cancer Res 62(18):5317-5324.
2. Aharinejad S, Paulus P, Sioud M, Hofmann M, Zins K, Schäfer R, Abraham D. 2004. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res 64(15):5378-5384.
3. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. 2008. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 66(1):1-9.
4. Allington TM, Schiemann WP. 2011. The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-b in mammary epithelial cells. Cells Tissues Organs 193(1-2):98-113.
5. Angelo LS, Kurzrock R. 2007. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 13(10):2825-2830.
6. Apte RN, Krelin Y, Song X, Dotan S, Recih E, Elkabets M, Voronov E. 2006. Effects of micro-environment-and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur J Cancer (Oxford, England: 1990) 42(6):751-759.
7. Arteaga CL, Tandon AK, Von Hoff DD, Osborne CK. 1988. Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res 48(14):3898-3904.
8. Balkwill F. 2009. Tumour necrosis factor and cancer. Nat Rev Cancer 9(5):361-371.
9. Band AM, Laiho M. 2011. Crosstalk of TGF-b and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 16(2):109-115.
10. Barone I, Catalano S, Gelsomino L, Marsico S, Giordano C, Panza S, Andò S. 2012. Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells. Cancer Res 72(6):1416-1427.
11. Baumgarten SC, Frasor J. 2012. Minireview: inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol Endocrinol 26(3):360-371.
12. Beckermann BM, Kallifatidis G, Groth A, Frommhold D, Apel A, Mattern J, Herr I. 2008. VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer 99(4):622-631.
13. Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpé S, Dirix LY. 2004. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 10(21):7157-7162.
14. Berger AM, Gerber LH, Mayer DK. 2012. Cancer-related fatigue: implications for breast cancer survivors. Cancer 118(8 Suppl):2261-2269.
15. Bierie B, Chung CH, Parker JS, Stover DG, Cheng N, Chytil A, Moses HL. 2009. Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest 119(6):1571-1582.
16. Biswas S, Nyman JS, Alvarez J, Chakrabarti A, Ayres A, Sterling J, Mundy GR. 2011. Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. PloS One 6(11):e27090.
17. Booth BW, Smith GH. 2007. Roles of transforming growth factor-alpha in mammary development and disease. Growth Factors 25(4):227-235.
18. Bower JE, Ganz PA, Aziz N, Fahey JL. 2002. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 64(4):604-611.
19. Bruunsgaard H, Pedersen M, Pedersen BK. 2001. Aging and proinflammatory cytokines. Curr Opin Hematol 8(3):131-136.
20. Byers T, Sedjo RL. 2011. Does intentional weight loss reduce cancer risk? Diabetes Obes Metab 13(12):1063-1072.
21. Cai D. 2009. NFkappaB-mediated metabolic inflammation in peripheral tissues versus central nervous system. Cell Cycle 8(16):2542-2548.
22. Caldefie-Chézet F, Damez M, de Latour M, Konska G, Mishellani F, Fusillier C, Vasson M-P. 2005. Leptin: a proliferative factor for breast cancer? Study on human ductal carcinoma. Biochem Biophys Res Commun 334(3):737-741.
23. Caldefie-Chezet F, Poulin A, Tridon A, Sion B, Vasson MP. 2001. Leptin: a potential regulator of polymorphonuclear neutrophil bactericidal action? J Leukoc Biol 69(3):414-418.
24. Caldefie-Chezet F, Poulin A, Vasson MP. 2003. Leptin regulates functional capacities of polymorphonuclear neutrophils. Free Radic Res 37(8):809-814.
25. Casey TM, Eneman J, Crocker A, White J, Tessitore J, Stanley M, Plaut K. 2008. Cancer associated fibroblasts stimulated by transforming growth factor beta1 (TGF-beta 1) increase invasion rate of tumor cells: a population study. Breast Cancer Res Treat 110(1):39-49.
26. Catalano S, Marsico S, Giordano C, Mauro L, Rizza P, Panno ML, Andò S. 2003. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem 278(31): 28668-28676.
27. Chauhan VP, Stylianopoulos T, Martin JD, Popović Z, Chen O, Kamoun WS, Jain RK. 2012. Normalization of tumour blood vessels improves the delivery of nanomedicines in a sizedependent manner. Nat Nanotechnol 7(6):383-388.
28. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissière F, Laune D, Lazennec G. 2007. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 9(1):R15.
29. Cheng N, Chytil A, Shyr Y, Joly A, Moses HL. 2008. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Mol Cancer Res 6(10):1521-1533.
30. Cleary MP, Grossmann ME. 2009. Minireview: Obesity and breast cancer: the estrogen connection. Endocrinology 150(6):2537-2542.
31. Collado-Hidalgo A, Bower JE, Ganz PA, Cole SW, Irwin MR. 2006. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res 12(9):2759-2766.
32. Connelly L, Barham W, Onishko HM, Sherrill T, Chodosh LA, Blackwell TS, Yull FE. 2011. Inhibition of NF-kappa B activity in mammary epithelium increases tumor latency and decreases tumor burden. Oncogene 30(12):1402-1412.
33. Coussens LM, Werb Z. 2002. Inflammation and cancer. Nature 420(6917):860-867.
34. Culig Z. 2011. Cytokine disbalance in common human cancers. Biochim Biophys Acta 1813(2):308-314.
35. D'Cruz CM, Moody SE, Master SR, Hartman JL, Keiper EA, Imielinski MB, Chodosh LA. 2002. Persistent parity-induced changes in growth factors, TGF-beta3, and differentiation in the rodent mammary gland. Mol Endocrinol 16(9):2034-2051.
36. D'Esposito V, Passaretti F, Hammarstedt A, Liguoro D, Terracciano D, Molea G, Formisano P. 2012. Adipocyte-released insulin-like growth factor-1 is regulated by glucose and fatty acids and controls breast cancer cell growth in vitro. Diabetologia 55(10):2811-2822.
37. Dai X-M, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S, Stanley ER. 2002. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 99(1):111-120.
38. Dave H, Trivedi S, Shah M, Shukla S. 2011. Transforming growth factor beta 2: a predictive marker for breast cancer. Indian J Exp Biol 49(11):879-887.
39. De Luca A, Gallo M, Aldinucci D, Ribatti D, Lamura L, D'Alessio A, Normanno N. 2011. Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. J Cell Physiol 226(8):2131-2138.
40. De Luca A, Lamura L, Gallo M, Maffia V, Normanno N. 2012. Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration. J Cell Biochem 113(11):3363-3370.
41. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Sotiriou C. 2007. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13(11):3207-3214.
42. Dieudonne M-N, Bussiere M, Dos Santos E, Leneveu M-C, Giudicelli Y, Pecquery R. 2006. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun 345(1):271-279.
43. Dinarello CA. 1996. Biologic basis for interleukin-1 in disease. Blood 87(6):2095-2147.
44. Donato NJ, Klostergaard J. 2004. Distinct stress and cell destruction pathways are engaged by TNF and ceramide during apoptosis of MCF-7 cells. Exp Cell Res 294(2):523-533.
45. Donovan J, Slingerland J. 2000. Transforming growth factorbeta and breast cancer: Cell cycle arrest by transforming growth factor-beta and its disruption in cancer. Breast Cancer Res 2(2):116-124.
46. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. 2000. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2(4):252-257.
47. Dunn LK, Mohammad KS, Fournier PGJ, McKenna CR, Davis HW, Niewolna M, Guise TA. 2009. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PloS One 4(9):e6896.
48. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, Weinberg RA. 2001. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 15(1):50-65.
49. Ernst M, Putoczki TL. 2012. Stat3: linking inflammation to (gastrointestinal) tumourigenesis. Clin Exp Pharmacol Physiol 39(8):711-718.
50. Ewan KBR, Oketch-Rabah HA, Ravani SA, Shyamala G, Moses HL, Barcellos-Hoff MH. 2005. Proliferation of estrogen receptor-alpha-positive mammary epithelial cells is restrained by transforming growth factor-beta1 in adult mice. Am J Pathol 167(2):409-417.
51. Faggioni R, Fantuzzi G, Fuller J, Dinarello CA, Feingold KR, Grunfeld C. 1998. IL-1 beta mediates leptin induction during inflammation. Am J Physiol 274(1 Pt 2):R204-R208.
52. Favaro E, Lord S, Harris AL, Buffa FM. 2011. Gene expression and hypoxia in breast cancer. Genome Med 3(8):55.
53. Fehniger TA, Cooper MA, Caligiuri MA. 2002. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 13(2):169-183.
54. Feng X-H, Liang Y-Y, Liang M, Zhai W, Lin X. 2002. Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGFbeta-mediated induction of the CDK inhibitor p15(Ink4B). Mol Cell 9(1):133-143.
55. Figueroa JD, Flanders KC, Garcia-Closas M, Anderson WF, Yang XR, Matsuno RK, Sherman ME. 2010. Expression of TGF-beta signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics. Breast Cancer Res Treat 121(3):727-735.
56. Franco-Barraza J, Valdivia-Silva JE, Zamudio-Meza H, Castillo A, Garc?á-Zepeda EA, Ben?tez-Bribiesca L, Meza I. 2010. Actin cytoskeleton participation in the onset of IL-1beta induction of an invasive mesenchymal-like phenotype in epithelial MCF-7 cells. Arch Med Res 41(3):170-181.
57. Fujita Y, Murakami M, Ogawa Y, Masuzaki H, Tanaka M, Ozaki S, Mimori T. 2002. Leptin inhibits stress-induced apoptosis of T lymphocytes. Clin Exp Immunol 128(1):21-26.
58. Gangemi S, Minciullo P, Adamo B, Franchina T, Ricciardi GRR, Ferraro M, Adamo V. 2012. Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. J Cell Biochem 113(6):2122-2125.
59. Glasgow E, Mishra L. 2008. Transforming growth factor-beta signaling and ubiquitinators in cancer. Endocr Relat Cancer 15(1):59-72.
60. Glinka Y, Prud'homme, G. J. 2008. Neuropilin-1 is a receptor for transforming growth factor beta-1, activates its latent form, and promotes regulatory T cell activity. J Leukoc Biol 84(1):302-310.
61. Goldberg JE, Schwertfeger KL. 2010. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets 11(9):1133-1146.
62. Goldstein RH, Reagan MR, Anderson K, Kaplan DL, Rosenblatt M. 2010. Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. Cancer Res 70(24):10044-10050.
63. Grau AM, Wen W, Ramroopsingh DS, Gao Y-T, Zi J, Cai Q, Zheng W. 2008. Circulating transforming growth factor-beta-1 and breast cancer prognosis: results from the Shanghai Breast Cancer Study. Breast Cancer Res Treat 112(2):335-341.
64. Grivennikov SI, Greten FR, Karin M. 2010. Immunity, inflammation, and cancer. Cell 140(6):883-899.
65. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. 2012. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38(7):904-910.
66. Hamed EA, Zakhary MM, Maximous DW. 2012. Apoptosis, angiogenesis, inflammation, and oxidative stress: basic interactions in patients with early and metastatic breast cancer. J Cancer Res Clin Oncol 138(6):999-1009.
67. Hamidullah, Changkija B, Konwar R. 2011. Role of interleukin-10 in breast cancer. Breast Cancer Res Treat 133(1):11-21.
68. Harvey SB, Wessely S, Kuh D, Hotopf M. 2009. The relationship between fatigue and psychiatric disorders: evidence for the concept of neurasthenia. J Psychosom Res 66(5):445-454.
69. He D, Li H, Yusuf N, Elmets CA, Li J, Mountz JD, Xu H. 2010. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloidderived suppressor cells. J Immunol 184(5):2281-2288.
70. Heldin C-H, Landström M, Moustakas A. 2009. Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelialmesenchymal transition. Curr Opin Cell Biol 21(2):166-176.
71. Honma S, Shimodaira K, Shimizu Y, Tsuchiya N, Saito H, Yanaihara T, Okai T. 2002. The influence of inflammatory cytokines on estrogen production and cell proliferation in human breast cancer cells. Endocr J 49(3):371-377.
72. Hou W-K, Xu Y-X, Yu T, Zhang L, Zhang W-W, Fu C-L, Chen L. 2007. Adipocytokines and breast cancer risk. Chin Med J 120(18):1592-1596.
73. Hsing C-H, Cheng H-C, Hsu Y-H, Chan C-H, Yeh C-H, Li C-F, Chang M-S. 2012. Upregulated IL-19 in breast cancer promotes tumor progression and affects clinical outcome. Clin Cancer Res 18(3):713-725.
74. Hsu Y-H, Hsing C-H, Li C-F, Chan C-H, Chang M-C, Yan J-J, Chang M-S. 2012. Anti-IL-20 monoclonal antibody suppresses breast cancer progression and bone osteolysis in murine models. J Immunol 188(4):1981-1991.
75. Hu X, Juneja SC, Maihle NJ, Cleary MP. 2002. Leptin- A growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst 94(22):1704-1711.
76. Humphreys RC, Hennighausen L. 2000. Transforming growth factor alpha and mouse models of human breast cancer. Oncogene 19(8):1085-1091.
77. Hung S-P, Ho JH, Shih Y-R. V, Lo T, Lee OK. 2012a. Hypoxia promotes proliferation and osteogenic differentiation potentials of human mesenchymal stem cells. J Orthop Res 30(2): 260-266.
78. Hung S-P, Yang M-H, Tseng K-F, Lee OK. 2012b. Hypoxiainduced secretion of TGF-beta 1 in mesenchymal stem cell promotes breast cancer cell progression. Cell Transplant 22(10):1869-1882.
79. Iguchi M, Aiba S, Yoshino Y, Tagami H. 2001. Human follicular papilla cells carry out nonadipose tissue production of leptin. J Invest Dermatol 117(6):1349-1356.
80. Iliopoulos D, Hirsch HA, Struhl K. 2009. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139(4):693-706.
81. Iliopoulos D, Hirsch HA, Wang G, Struhl K. 2011. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci USA 108(4):1397-1402.
82. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. 2010. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 39(4):493-506.
83. Imamura T, Hikita A, Inoue Y. 2012. The roles of TGF-b signaling in carcinogenesis and breast cancer metastasis. Breast Cancer 19(2):118-124.
84. Inman GJ. 2011. Switching TGFb from a tumor suppressor to a tumor promoter. Curr Opin Genet Dev 21(1):93-99.
85. Irahara N, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S. 2006. Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-alpha, IL-6 and COX-2 mRNAs in human breast cancer. Int J of Cancer 118(8): 1915-1921.
86. Ivanović V, Dedović-Tanić N, Milovanović Z, Lukić S, Nikolić S, Baltić V, Dimitrijević B. 2009. Quantification of transforming growth factor beta 1 levels in metastatic axillary lymph node tissue extracts from breast cancer patients: a new specimen source. Anal Quant Cytol Histol 31(5):288-295.
87. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Miller LD. 2006. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66(21):10292-10301.
88. Jain P, Alahari SK. 2011. Breast cancer stem cells: a new challenge for breast cancer treatment. Front Biosci 16:1824-1832.
89. Jardé T, Caldefie-Chézet F, Damez M, Mishellany F, Penault-Llorca F, Guillot J, Vasson MP. 2008. Leptin and leptin receptor involvement in cancer development: a study on human primary breast carcinoma. Oncol Rep 19(4):905-911.
90. Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A, Schwall R, Rosen EM. 1997. Expression of interleukin-1beta in human breast carcinoma. Cancer 80(3):421-434.
91. Joffroy CM, Buck MB, Stope MB, Popp SL, Pfizenmaier K, Knabbe C. 2010. Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer. Cancer Res 70(4):1314-1322.
92. Joshi A, Cao D. 2010. TGF-beta signaling, tumor microenvironment and tumor progression: the butterfly effect. Front Biosci 15:180-194.
93. Juárez P, Guise TA. 2010. Tgf-Beta pathway as a therapeutic target in bone metastases. Curr Pharm Des 16(11):1301-1312.
94. Jung Y-J, Isaacs JS, Lee S, Trepel J, Neckers L. 2003. IL-1betamediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 17(14):2115-2117.
95. Kalluri R, Weinberg RA. 2009. The basics of epithelialmesenchymal transition. J Clin Invest 119(6):1420-1428.
96. Kamel M, Shouman S, El-Merzebany M, Kilic G, Veenstra T, Saeed M, Salama S. 2012. Effect of tumour necrosis factoralpha on estrogen metabolic pathways in breast cancer cells. J Cancer 3:310-321.
97. Kang JH, Lee YY, Yu BY, Yang B-S, Cho K-H, Yoon DK, Roh YK. 2005. Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res 28(11): 1263-1269.
98. Karayiannakis AJ, Syrigos KN, Polychronidis A, Pitiakoudis M, Bounovas A, Simopoulos K. 2001. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res 21(2B):1355-1358.
99. Karin M, Greten FR. 2005. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5(10):749-759.
100. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Weinberg RA. 2007. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449(7162):557-563.
101. Kelly RJ, Morris JC. 2010. Transforming growth factor-beta: a target for cancer therapy. J Immunotoxicol 7(1):15-26.
102. Kim KY, Jeong SY, Won J, Ryu PD, Nam MJ. 2001. Induction of angiogenesis by expression of soluble type II transforming growth factor-beta receptor in mouse hepatoma. J Biol Chem 276(42):38781-38786.
103. Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL, Rimm DL. 2004. Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin Cancer Res 10(1 Pt 1):173-177.
104. Knüpfer H, Preiss R. 2007. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 102(2): 129-135.
105. Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I, Orimo A. 2010. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci USA 107(46):20009-20014.
106. Koli KM, Arteaga CL. 1997. Predominant cytosolic localization of type II transforming growth factor beta receptors in human breast carcinoma cells. Cancer Res 57(5):970-977.
107. Korkaya H, Kim G-I, Davis A, Malik F, Henry NL, Ithimakin S, Wicha MS. 2012. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2 + breast cancer by expanding the cancer stem cell population. Mol Cell 47(4): 570-584.
108. Korkaya H, Liu S, Wicha MS. 2011. Review series Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest 121(10):3804-3809.
109. Koz1owski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ. 2003. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bia1ymst 48:82-84.
110. Krishnamurthy P, Schuetz JD. 2006. Role of ABCG2/BCRP in biology and medicine. Ann Rev Pharmacol Toxicol 46:381-410.
111. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Oft M. 2006. IL-23 promotes tumour incidence and growth. Nature 442(7101):461-465.
112. Laud K, Gourdou I, Pessemesse L, Peyrat JP, Djiane J. 2002. Identification of leptin receptors in human breast cancer: functional activity in the T47-D breast cancer cell line. Mol Cell Endocrinol 188(1-2):219-226.
113. Laverty HG, Wakefield LM, Occleston NL, O'Kane S, Ferguson MWJ. 2009. TGF-beta3 and cancer: a review. Cytokine Growth Factor Rev 20(4):305-317.
114. Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE. 1998. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 77(12):2246-2251.
115. Lewis AM, Varghese S, Xu H, Alexander HR. 2006. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 4:48.
116. Lin EY, Nguyen AV, Russell RG, Pollard JW. 2001. Colonystimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193(6):727-740.
117. Lin S, Yang J, Elkahloun AG, Bandyopadhyay A, Wang L, Cornell JE, Sun L-Z. 2012. Attenuation of TGF-b signaling suppresses premature senescence in a p21-dependent manner and promotes oncogenic Ras-mediated metastatic transformation in human mammary epithelial cells. Mol Biol Cell 23(8):1569-1581.
118. Lis CG, Gupta D, Grutsch JF. 2008. The relationship between insomnia and patient satisfaction with quality of life in cancer. Support Care Cancer 16(3):261-266.
119. Liu J, Liao S, Diop-frimpong B, Chen W, Goel S, Naxerova K, Xu L. 2012a. TGF-b blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci USA 109(41):16618-16623.
120. Liu L, Mills PJ, Rissling M, Fiorentino L, Natarajan L, Dimsdale JE, Ancoli-Israel S. 2012b. Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy. Brain Behav Immun 26(5):706-713.
121. Lyon DE, McCain NL, Walter J, Schubert C. 2008. Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nurs Res 57(1):51-58.
122. Maher MG, Sapi E, Turner B, Gumbs A, Perrotta PL, Carter D, Haffty BG. 1998. Prognostic significance of colony-stimulating factor receptor expression in ipsilateral breast cancer recurrence. Clin Cancer Res 4(8):1851-1856.
123. Malekshah OM, Lage H, Bahrami AR, Afshari JT, Behravan J. 2012. PXR and NF-kB correlate with the inducing effects of IL-1b and TNF- A on ABCG2 expression in breast cancer cell lines. Eur J Pharm Sci 47(2):474-480.
124. Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY, Weinberg RA. 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704-715.
125. Martń-Romero C, Santos-Alvarez J, Goberna R, Sánchez-Margalet V. 2000. Human leptin enhances activation and proliferation of human circulating T lymphocytes. Cell Immunol 199(1):15-24.
126. Massagué J. 2008. TGFbeta in Cancer. Cell 134(2):215-230.
127. Merendino RA, Arena A, Capozza AB, Chillemi S, Mesiti M. 1996. Serum levels of interleukin-10 in patients affected by breast cancer. Immunol Lett 53(1):59-60.
128. Meulmeester E, Ten Dijke P. 2011. The dynamic roles of TGFb in cancer. J Pathol 223(2):205-218.
129. Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR. 1994. Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer 56(6):777-782.
130. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Bergh J. 2005. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102(38):13550-13555.
131. Miller LJ, Kurtzman SH, Anderson K, Wang Y, Stankus M, Renna M, Kreutzer DL. 2000. Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. Cancer Invest 18(4):293-302.
132. Mills PJ, Parker B, Dimsdale JE, Sadler GR, Ancoli-Israel S. 2005. The relationship between fatigue and quality of life and inflammation during anthracycline-based chemotherapy in breast cancer. Biol Psychol 69(1):85-96.
133. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, Noguchi S. 2003. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 9(15):5699-5704.
134. Molloy AP, Martin FT, Dwyer RM, Griffin TP, Murphy M, Barry FP, Kerin MJ. 2009. Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. Int J Cancer 124(2):326-332.
135. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. 2001. Interleukin-10 and the interleukin-10 receptor. Ann Rev Immunol 19:683-765.
136. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. 1993. Interleukin-10. Ann Rev Immunol 11:165-190.
137. Mor G, Yue W, Santen RJ, Gutierrez L, Eliza M, Berstein LM, Naftolin F. 1998. Macrophages, estrogen and the microenvironment of breast cancer. J Steroid Biochem Mol Biol 67(5-6):403-411.
138. Morandi A, Barbetti V, Riverso M, Dello Sbarba P, Rovida E. 2011. The colony-stimulating factor-1 (CSF-1) receptor sustains ERK1/2 activation and proliferation in breast cancer cell lines. PloS One 6(11):e27450.
139. Mosaffa F, Lage H, Afshari JT, Behravan J. 2009. Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX. Inflamm Res 58(10):669-676.
140. Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, Oft M. 2011. IL-10 elicits IFNg-dependent tumor immune surveillance. Cancer Cell 20(6):781-796.
141. Naber HPH, Wiercinska E, Ten Dijke P, van Laar T. 2011. Spheroid assay to measure TGF-b-induced invasion. J Vis Exp (57):1-7.
142. Naik MU, Naik TU, Suckow AT, Duncan MK, Naik UP. 2008. Attenuation of junctional adhesion molecule-A is a contributing factor for breast cancer cell invasion. Cancer Res 68(7):2194-2203.
143. Naritxa D, Seclaman E, Ursoniu S, Ilina R, Cireap N, Anghel A. 2011. Expression of CCL18 and interleukin-6 in the plasma of breast cancer patients as compared with benign tumor patients and healthy controls. Rom J Morphol Embryol 52(4):1261-1267.
144. Nicolini A, Carpi A. 2008. Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumor cell biology. Med Res Rev 29(3):436-471.
145. Nicolini A, Carpi A, Rossi G. 2006. Cytokines in breast cancer. Cytokine Growth Factor Rev 17(5):325-337.
146. Novitskiy SV, Pickup MW, Gorska AE, Owens P, Chytil A, Aakre M, Moses HL. 2011. TGF-b receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms. Cancer Discov 1(5):430-441
147. O'brien SN, Welter BH, Price TM. 1999. Presence of leptin in breast cell lines and breast tumors. Biochem Biophys Res Commun 259(3):695-698.
148. Opp MR. 2005. Cytokines and sleep. Sleep Med Rev 9(5):355-364.
149. Orimo A, Weinberg RA. 2006. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 5(15):1597-1601.
150. Ostman A, Augsten M. 2009. Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr Opin Genet Dev 19(1):67-73.
151. Otero M, Lago R, Gómez R, Lago F, Gómez-Reino JJ, Gualillo O. 2006. Leptin: a metabolic hormone that functions like a proinflammatory adipokine. Drug News Perspect 19(1): 21-26.
152. Ouchi N, Parker JL, Lugus JJ, Walsh K. 2011. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11(2):85-97.
153. Pantschenko AG, Pushkar I, Anderson KH, Wang Y, Miller LJ, Kurtzman SH, Kreutzer DL. 2003. The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. Int J Oncol 23(2):269-284.
154. Patel LR, Camacho DF, Shiozawa Y, Pienta KJ. 2012. Mechanisms of cancer cell metastasis to the bone: a multistep process. Future Oncol 7(11):1285-1297.
155. Perk J, Iavarone A, Benezra R. 2005. Id family of helix-loophelix proteins in cancer. Nat Rev Cancer 5(8):603-614.
156. Perrier S, Caldefie-Chézet F, Vasson M-P. 2009. IL-1 family in breast cancer: potential interplay with leptin and other adipocytokines. FEBS Lett 583(2):259-265.
157. Peter R, Stefania M, Ping LJ, Marcel Z, Josef B, Markus H. 2013. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. Cochrane Database Syst Rev 10: CD007913.
158. Pfeilschifter J, Köditz R, Pfohl M, Schatz H. 2002. Changes in proinflammatory cytokine activity after menopause. Endocrine Rev 23(1):90-119.
159. Podsypanina K, Du Y-CN, Jechlinger M, Beverly LJ, Hambardzumyan D, Varmus H. 2008. Seeding and propagation of untransformed mouse mammary cells in the lung. Science 321(5897):1841-1844.
160. Pradhan M, Bembinster LA, Baumgarten SC, Frasor J. 2010. Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF{kappa}B cooperativity at adjacent response elements. J Biol Chem 285(41):31100-31106.
161. Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H. 2001. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 12(3):129-135.
162. Rafiq S, Stevens K, Hurst AJ, Murray A, Henley W, Weedon MN, Frayling TM. 2007. Common genetic variation in the gene encoding interleukin-1-receptor antagonist (IL-1RA) is associated with altered circulating IL-1RA levels. Genes Immun 8(4):344-351.
163. Raison CL, Rye DB, Woolwine BJ, Vogt GJ, Bautista BM, Spivey JR, Miller AH. 2010. Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol. Biol Psychiatry 68(10):942-949.
164. Reichlin S, Chen G, Nicolson M. 2000. Blood to brain transfer of leptin in normal and interleukin-1beta-treated male rats. Endocrinology 141(6):1951-1954.
165. Reyes-Gibby CC, Wu X, Spitz M, Kurzrock R, Fisch M, Bruera E, Shete S. 2008. Molecular epidemiology, cancer-related symptoms, and cytokines pathway. Lancet Oncol 9(8):777-785.
166. Sabe H. 2011. Cancer early dissemination: cancerous epithelialmesenchymal transdifferentiation and transforming growth factor b signalling. J Biochem 149(6):633-639.
167. Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE, Hall BM. 2007. Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. FASEB J 21(13): 3763-3770.
168. Scholl SM, Pallud C, Beuvon F, Hacene K, Stanley ER, Rohrschneider L, Lidereau R. 1994. Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 86(2):120-126.
169. Schultz SL, Dalton SO, Christensen J, Carlsen K, Ross L, Johansen C. 2011. Factors correlated with fatigue in breast cancer survivors undergoing a rehabilitation course, Denmark, 2002-2005. Psycho Oncol 20(4):352-360.
170. Serra R, Easter SL, Jiang W, Baxley SE. 2011. Wnt5a as an effector of TGFb in mammary development and cancer. J Mammary Gland Biol Neoplasia 16(2):157-167.
171. Shangguan L, Ti X, Krause U, Hai B, Zhao Y, Yang Z, Liu F. 2012. Inhibition of TGF-b/Smad signaling by BAMBI blocks differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and abolishes their protumor effects. Stem Cells 30(12):2810-2819.
172. Sheen-Chen SM, Chen WJ, Eng HL, Chou FF. 1997. Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res Treat 43(3):211-215.
173. Sherr CJ, Rettenmier CW, Sacca R, Roussel MF, Look AT, Stanley ER. 1985. The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell 41(3):665-676.
174. Shi Z, Yang W-M, Chen L-P, Yang D-H, Zhou Q, Zhu J, Huang R-P. 2012. Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production. Breast Cancer Res Treat 135(3): 737-747.
175. Simeone A-M, Nieves-Alicea R, McMurtry VC, Colella S, Krahe R, Tari AM. 2007. Cyclooxygenase-2 uses the protein kinase C/interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells. Int J Oncol 30(4):785-792.
176. Singer CF, Kronsteiner N, Hudelist G, Marton E, Walter I, Kubista M, Kubista E. 2003. Interleukin 1 system and sex steroid receptor expression in human breast cancer: interleukin 1alpha protein secretion is correlated with malignant phenotype. Clin Cancer Res 9(13):4877-4883.
177. Singh G, Singh SK, König A, Reutlinger K, Nye MD, Adhikary T, Ellenrieder V. 2010. Sequential activation of NFAT and c-Myc transcription factors mediates the TGF-beta switch from a suppressor to a promoter of cancer cell proliferation. J Biol Chem 285(35):27241-27250.
178. Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, Bendriss-Vermare N. 2012. Impaired IFN- A production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res 72(20):5188-5197.
179. Snoussi K, Mahfoudh W, Bouaouina N, Ahmed SB, Helal AN, Chouchane L. 2006. Genetic variation in IL-8 associated with increased risk and poor prognosis of breast carcinoma. Hum Immunol 67(1-2):13-21.
180. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Delorenzi M. 2006. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98(4):262-272.
181. Srabovic N, Mujagic Z, Mujanovic-mustedanagic J, Muminovic Z, Softic A, Begic L. 2011. Interleukin 13 expression in the primary breast cancer tumor tissue. Biochem Medica 21(2): 131-138.
182. Starkweather AR, Lyon DE, Schubert CM. 2013. Pain and inflammation in women with early-stage breast cancer prior to induction of chemotherapy. Biol Res Nurs 15(2):234-241.
183. Studebaker AW, Storci G, Werbeck JL, Sansone P, Sasser AK, Tavolari S, Hall BM. 2008. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 68(21):9087-9095.
184. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, Hall BM. 2009. Interleukin-6 induces an epithelialmesenchymal transition phenotype in human breast cancer cells. Oncogene 28(33):2940-2947.
185. Swain SL. 1991. Lymphokines and the immune response: the central role of interleukin-2. Curr Opin Immunol 3(3):304-310.
186. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Mani SA. 2010. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA 107(35):15449-15454.
187. Tian M, Schiemann WP. 2010. PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis. FASEB J 24(4):1105-1116.
188. Tilg H, Moschen AR. 2006. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6(10):772-783.
189. Van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AAM, Voskuil DW, Bernards R. 2002. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999-2009.
190. Van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. 2007. High prevalence of pain in patients with cancer in a large populationbased study in The Netherlands. Pain 132(3):312-320.
191. Van der Auwera I, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, Colpaert CG, Dirix LY. 2004. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res 10(23):7965-7971.
192. Vazquez-Martin A, Colomer R, Menendez JA. 2007. Protein array technology to detect HER2 (erbB-2)-induced "cytokine signature" in breast cancer. Eur J Cancer 43(7):1117-1124.
193. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. 2006. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24(2):179-189.
194. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. 1997. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab 82(5):1313-1316.
195. Vincent T, Neve EPA, Johnson JR, Kukalev A, Rojo F, Albanell J, Fuxe J. 2009. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-b mediated epithelial-mesenchymal transition. Nat Cell Biol 11(8):943-950.
196. Voulgari A, Pintzas A. 2009. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 1796(2):75-90.
197. Walter M, Liang S, Ghosh S, Hornsby PJ, Li R. 2009. Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene 28(30): 2745-2755.
198. Wang F, Liu H, Liu S, Tang S, Yang L, Feng G. 2005. SHP-2 promoting migration and metastasis of MCF-7 with loss of Ecadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1beta in vivo and in vitro. Breast Cancer Res Treat 89(1):5-14.
199. Wang Y, Lui W-Y. 2012. Transforming growth factor-b1 attenuates junctional adhesion molecule-A and contributes to breast cancer cell invasion. Eur J Cancer 48(18):3475-3487.
200. Weigert A, Tzieply N, von Knethen A, Johann AM, Schmidt H, Geisslinger G, Brüne B. 2007. Tumor cell apoptosis polarizes macrophages role of sphingosine-1-phosphate. Mol Biol Cell 18(10):3810-3819.
201. Wendt MK, Allington TM, Schiemann WP. 2009. Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol 5(8):1145-1168.
202. Wilson TJ, Nannuru KC, Futakuchi M, Singh RK. 2010. Cathepsin G-mediated enhanced TGF-beta signaling promotes angiogenesis via upregulation of VEGF and MCP-1. Cancer Lett 288(2):162-169.
203. Wolf JS, Chen Z, Dong G, Sunwoo JB, Bancroft CC, Capo DE, Van Waes C. 2001. IL (interleukin)-1alpha promotes nuclear factor-kappaB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res 7(6):1812-1820.
204. Wu M-H, Chou Y-C, Chou W-Y, Hsu G-C, Chu C-H, Yu C-P, Sun C-A. 2009. Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer 100(4):578-582.
205. Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Condeelis J. 2004. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 64(19):7022-7029.
206. Xie G, Yao Q, Liu Y, Du S, Liu A, Guo Z, Yuan Y. 2012. IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures. Int J Oncol 40(4):1171-1179.
207. Xie Y, Sheng W, Xiang J, Ye Z, Zhu Y, Chen X, Yang J. 2008. Recombinant human IL-24 suppresses lung carcinoma cell growth via induction of cell apoptosis and inhibition of tumor angiogenesis. Cancer Biother Radiopharm 23(3):310-320.
208. Xu J, Lamouille S, Derynck R. 2009. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19(2):156-172.
209. Yilmaz M, Christofori G. 2009. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 28(1-2):15-33.
210. Yin X, Wolford CC, Chang Y-S, McConoughey SJ, Ramsey SA, Aderem A, Hai T. 2010. ATF3, an adaptive-response gene, enhances TGF{beta} signaling and cancer-initiating cell features in breast cancer cells. J Cell Sci 123(Pt 20):3558-3565.
211. Yin Y, Chen X, Shu Y. 2009. Gene expression of the invasive phenotype of TNF-alpha-treated MCF-7 cells. Biomed Pharmacother 63(6):421-428.
212. Yoshimura A, Wakabayashi Y, Mori T. 2010. Cellular and molecular basis for the regulation of inflammation by TGFbeta. J Biochem 147(6):781-792.
213. Yu Y, Wang Y, Ren X, Tsuyada A, Li A, Liu LJ, Wang SE. 2010. Context-dependent bidirectional regulation of the MutS homolog 2 by transforming growth factor b contributes to chemoresistance in breast cancer cells. Mol Cancer Res 8(12):1633-1642.
214. Zhang GJ, Adachi I. 1999. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 19(2B):1427-1432.
215. Zhao Y, Sun R, You L, Gao C, Tian Z. 2003. Expression of leptin receptors and response to leptin stimulation of human natural killer cell lines. Biochem Biophys Res Commun 300(2):247-252.
216. Zheng LM, Ojcius DM, Garaud F, Roth C, Maxwell E, Li Z, King I. 1996. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 184(2):579-584.
217. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Littman DR. 2007. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 8(9):967-974.
218. Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H, Rose DW. 2006. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 124(3):615-629.
219. Ziober BL, Willson JK, Hymphrey LE, Childress-Fields K, Brattain MG. 1993. Autocrine transforming growth factoralpha is associated with progression of transformed properties in human colon cancer cells. J Biol Chem 268(1): 691-698.
220. Zu X, Zhang Q, Cao R, Liu J, Zhong J, Wen G, Cao D. 2012. Transforming growth factor-b signaling in tumor initiation, progression and therapy in breast cancer: an update. Cell Tissue Res 347(1):73-84.
221. Zuccari DAPDC, Leonel C, Castro R, Gelaleti GB, Jardim BV, Moscheta MG, Esteves JL. 2012. An immunohistochemical study of interleukin-8 (IL-8) in breast cancer. Acta Histochem 114(6):571-576.